Finally, kidney disease meets a true opponent
We’re pioneering precision-based medicines to revolutionize the treatment of kidney diseases.
A global epidemic with an innovation gap
Chronic kidney disease (CKD) affects 780 million people globally–that’s one in every ten people. Progression to end-stage kidney disease is common, and severely impacts quality of life. Despite this, fewer than 1% of all research programs across the biopharmaceutical industry are focused on reducing the substantial burden of CKD.
Learn more about the problem we aim to solve
780M
People worldwide with CKD
10M
People die annually from kidney disease worldwide
<1%
Of all active pipeline programs in the biopharmaceutical industry are for kidney diseases
Our Precision Medicine Approach to Treat Kidney Disease, Starting with FSGS
We are applying precision medicine to discover, develop and commercialize disease-modifying kidney disease treatments. We believe our approach enables us to uncover subsets of patients based on genetic and environmental factors within heterogenous kidney diseases.
We have a robust pipeline of novel, clinical-stage, precision medicine product candidates, including or lead program, GFB-887 for TRPC5-mediated FSGS. All of our programs target kidney diseases with significant unmet medical needs
Our Precision Medicine Product Engine: Integrating Kidney Genetics & Biology
Our product engine allows us to discover, validate and drug novel targets while identifying FSGS patient subsets most likely to respond to our treatments.
There are so many people with kidney disease, me included, who are struggling every day to live life and to live it with some sense of quality. We need to find solutions because dialysis and transplants are not great solutions.
Living with FSGS
A bold mission to transform the lives of people living with FSGS and other kidney diseases
Our Mission
To deliver disease-modifying precision medicines that bring hope and renewed quality of life to people living with kidney diseases.
Our Vision
We aspire to save kidneys and end dialysis.
The Feeder Interview Series
Check out our new interview series, The Feeder. We’re speaking with people impacted by kidney disease, and a wide range of experts who are driving change, innovation and hope in the kidney space.
Latest news
See all media
08.10.2021
Goldfinch Bio Announces Initiation of Open-Label Extension Study for Patients with Focal Segmental Glomerular Sclerosis (FSGS) Enrolled in Phase 2 Clinical Trial of GFB-887
Read More
08.03.2021
Goldfinch Bio to Present at the 2021 Wedbush PacGrow Healthcare Virtual Conference
Read More
07.27.2021
Goldfinch Bio Announces Upcoming Presentations at the 13th International Podocyte Conference
Read More
Become a Finch
Join Us!
We aspire to be the world’s leading precision medicine kidney company – dedicated to our mission, focused on pursuing world-class science and fully committed to improving the lives of people with FSGS and other kidney diseases.